3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
6
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Gastrointestinal
4
Thoracic
3
Sarcoma
3
Plasma cell
2
Gynecologic
2
Genitourinary
2
Breast
2
Other neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Dermatologic
1
Conditions
Melanoma
312
Carcinoma, Basal Cell
60
Skin Neoplasms
53
Lymphoma, T-Cell, Cutaneous
37
Breast Neoplasms
31
Uveal Melanoma
29
Neoplasms
27
Lung Neoplasms
27
Carcinoma, Non-Small-Cell Lung
27
Keratosis, Actinic
25
Neoplasm Metastasis
24
Carcinoma, Squamous Cell
22
Carcinoma, Renal Cell
21
Lymphoma
17
Mycosis Fungoides
16
Lymphoma, Large B-Cell, Diffuse
15
Hodgkin Disease
15
Urinary Bladder Neoplasms
14
Sezary Syndrome
14
Pancreatic Neoplasms
14
Lymphoma, Non-Hodgkin
14
Lymphoma, Follicular
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Ovarian Neoplasms
13
Lymphoma, Mantle-Cell
13
Lymphoma, B-Cell, Marginal Zone
13
Colorectal Neoplasms
13
Burkitt Lymphoma
13
Lymphoma, Large-Cell, Immunoblastic
12
Interventions
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
Dermatologic
×
Clear all
NCT03638375
2023-12-12
ACTME
Leiden University Medical Center
Phase 1/2
Unknown
34 enrolled